InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,022.21
(
-0.58%
)
US TECH 100
17,060.00
(
-1.07%
)
Dow Jones
37,753.31
(
-0.12%
)
Brent Oil
87.02
(
0.03%
)
Bitcoin
61,886.80
(
0.99%
)
Post# of 251500
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 825
Posts 119423
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 206654

Monday, 12/05/2016 7:18:55 PM

Monday, December 05, 2016 7:18:55 PM

Post# of 251500
Reuters' saying that Gazyva/Treanda vs Rituxan/Treanda raised 3-year survival from 92% to "only" 94% makes the benefit sound trifling, but it's actually a 25% reduction in the risk of death during the first three years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up